Zoetis (BSP:Z1TS34) Inventories, Finished Goods : R$5,620 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Zoetis Inventories, Finished Goods?

Zoetis's quarterly finished goods increased from Jun. 2023 (R$5,480 Mil) to Sep. 2023 (R$5,852 Mil) but then declined from Sep. 2023 (R$5,852 Mil) to Dec. 2023 (R$5,620 Mil).

Zoetis's annual finished goods increased from Dec. 2021 (R$5,022 Mil) to Dec. 2022 (R$5,717 Mil) but then declined from Dec. 2022 (R$5,717 Mil) to Dec. 2023 (R$5,620 Mil).

Zoetis Inventories, Finished Goods Historical Data

The historical data trend for Zoetis's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Inventories, Finished Goods Chart

Zoetis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

2,877.26

4,141.48

5,021.55

5,717.49

5,620.07

Zoetis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventories, Finished Goods	Get a 7-Day Free Trial															5,717.49	5,547.16	5,479.83	5,852.36	5,620.07

Zoetis Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Zoetis (BSP:Z1TS34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (BSP:Z1TS34) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

ZTS:USA ZTS:Mexico 1ZTS:Italy ZOE:Germany

Address

10 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.zoetis.com

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis (BSP:Z1TS34) Headlines

No Headlines